Form 4: BIOADAPTIVES Director Receives Equity Compensation

BIOADAPTIVES, Inc. Director Mark P. Frissora was granted 1,382 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Director Mark P. Frissora of BIOADAPTIVES, INC. (BDPT) received 1,382 shares of Series D Convertible Preferred Stock.
• This compensation is for board services, as per a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock.
• Conversion is subject to a 4.9% beneficial ownership limitation.
• Conversion cannot occur until six months after the issuance date (May 1, 2026), except in the case of liquidation.
• Each preferred share carries 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation.
• The right to convert does not expire.
• Following this transaction, Mr. Frissora directly beneficially owns 52,906 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports a standard equity compensation grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns management interests with shareholders, though it introduces potential future dilution.

Positives

• Issuance of equity compensation to Director Mark P. Frissora aligns his interests with those of shareholders.
• The Series D Convertible Preferred Stock provides significant voting power (100 votes per share), giving the director a strong voice in company matters.

Negatives

• Potential future dilution for common shareholders upon conversion of the Series D Convertible Preferred Stock.

Risks

• Future dilution of common stock if the Series D Convertible Preferred Stock is converted.

Industry Context

This is a routine insider transaction report. Equity compensation for directors is a common practice across various industries to incentivize long-term performance and align interests with shareholders.

Corporate Governance

Related Party Transactions

• Issuance of 1,382 shares of Series D Convertible Preferred Stock to Director Mark P. Frissora as compensation for board services.

Stakeholder Impact

• Shareholders: Potential for future dilution upon conversion of preferred stock, but also increased alignment of director's interests with shareholder value.
• Director (Mark P. Frissora): Receives equity compensation, increasing his stake and voting power in the company.

Next Steps

• Conversion of Series D Convertible Preferred Stock into common stock after May 1, 2026, subject to beneficial ownership limitations.

Key Dates

Keywords

BIOADAPTIVES, BDPT, Mark P. Frissora, Form 4, Director Compensation, Series D Convertible Preferred Stock, Equity Compensation, Insider Transaction, Corporate Governance